Our mission is safe and affordable medicines
Follow the news of our company!
University of Washington (UW) researchers have developed the thermal earring, a new wearable they say outperforms smartwatches in measuring a wearer’s skin temperature during periods of rest. The earring has also shown promise for monitoring signs of stress, eating, exercise, and ovulation, according to a statement. UW’s prototype smart earring—which is not currently commercially available—is about the size and weight of a small paper clip and boasts a 28-day battery life. A magnetic clip attaches one temperature sensor to a wearer’s ear, while a second sensor dangles below it and estimates room temperature. The second sensor can include fashion designs made of resin or gemstones, without negatively affecting its accuracy. The earring contains a Bluetooth chip, a battery, two temperature sensors, and an antenna. After reading and sending a person’s temperature, it goes into deep sleep to save power. “I wear a smartwatch to track my personal health, but I’ve found that a lot of people think smartwatches are unfashionable or bulky and uncomfortable,” said Qiuyue (Shirley) Xue, a UW doctoral student in the Paul G. Allen School of Computer Science & Engineering, in a statement. “I also like to wear earrings, so we started thinking about what unique things we can get from the earlobe,” added Xue, who coauthored a study on the thermal earring published earlier this year in a technology journal. “We found that sensing the skin temperature on the lobe, instead of a hand or wrist, was much more accurate. It also gave us the option to have part of part of the sensor dangle to separate ambient room temperature from skin temperature.” Xue’s statement said that “current wearables like Apple Watch and Fitbit have temperature sensors, but they provide only an average temperature for the day, and their temperature readings from wrists and hands are too noisy to track ovulation.” Eventually, Xue said, she hoped to develop a full jewelry set for health monitoring. “The earrings would sense activity and health metrics such as temperature and heart rate,” she explained, “while a necklace might serve as an electrocardiogram monitor for more effective heart health data.”
Using a type of artificial intelligence known as deep learning, MIT researchers have discovered a class of compounds that can kill a drug-resistant bacterium that causes more than 10,000 deaths in the United States every year. In a study appearing today in Nature, the researchers showed that these compounds could kill methicillin-resistant Staphylococcus aureus (MRSA) grown in a lab dish and in two mouse models of MRSA infection. The compounds also show very low toxicity against human cells, making them particularly good drug candidates. A key innovation of the new study is that the researchers were also able to figure out what kinds of information the deep-learning model was using to make its antibiotic potency predictions. This knowledge could help researchers to design additional drugs that might work even better than the ones identified by the model. “The insight here was that we could see what was being learned by the models to make their predictions that certain molecules would make for good antibiotics. Our work provides a framework that is time-efficient, resource-efficient, and mechanistically insightful, from a chemical-structure standpoint, in ways that we haven’t had to date,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering. Felix Wong, a postdoc at IMES and the Broad Institute of MIT and Harvard, and Erica Zheng, a former Harvard Medical School graduate student who was advised by Collins, are the lead authors of the study, which is part of the Antibiotics-AI Project at MIT. The mission of this project, led by Collins, is to discover new classes of antibiotics against seven types of deadly bacteria, over seven years. MRSA, which infects more than 80,000 people in the United States every year, often causes skin infections or pneumonia. Severe cases can lead to sepsis, a potentially fatal bloodstream infection. Over the past several years, Collins and his colleagues in MIT’s Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) have begun using deep learning to try to find new antibiotics. Their work has yielded potential drugs against Acinetobacter baumannii, a bacterium that is often found in hospitals, and many other drug-resistant bacteria. These compounds were identified using deep learning models that can learn to identify chemical structures that are associated with antimicrobial activity. These models then sift through millions of other compounds, generating predictions of which ones may have strong antimicrobial activity. Experiments revealed that the compounds appear to kill bacteria by disrupting their ability to maintain an electrochemical gradient across their cell membranes. This gradient is needed for many critical cell functions, including the ability to produce ATP (molecules that cells use to store energy). An antibiotic candidate that Collins’ lab discovered in 2020, halicin, appears to work by a similar mechanism but is specific to Gram-negative bacteria (bacteria with thin cell walls). MRSA is a Gram-positive bacterium, with thicker cell walls. “We have pretty strong evidence that this new structural class is active against Gram-positive pathogens by selectively dissipating the proton motive force in bacteria,” Wong says. “The molecules are attacking bacterial cell membranes selectively, in a way that does not incur substantial damage in human cell membranes. Our substantially augmented deep learning approach allowed us to predict this new structural class of antibiotics and enabled the finding that it is not toxic against human cells.” The researchers have shared their findings with Phare Bio, a nonprofit started by Collins and others as part of the Antibiotics-AI Project. The nonprofit now plans to do more detailed analysis of the chemical properties and potential clinical use of these compounds. Meanwhile, Collins’ lab is working on designing additional drug candidates based on the findings of the new study, as well as using the models to seek compounds that can kill other types of bacteria.
People are being maimed by unauthorized fat-dissolving injections meant to tighten up double chins and dissipate flab along the arms, thighs and stomach, the U.S. Food and Drug Administration warns. The shots are supposed to break down fat cells and reduce fat deposits in the areas around the injection sites. But adverse reactions from the unapproved injections are causing scarring, skin deformities, cysts, painful knots, and serious infections, the FDA said in an agency news release. The unapproved injections are being marketed under brand names like Aqualyx, Lipodissolve, Lipo Lab and Kabelline, the FDA said. Common ingredients in the injections include phosphatidylcholine (PPC) and sodium deoxycholate (DC). These ingredients have been used alone or together and are sometimes referred to as "PCDC injections." The FDA has received reports of consumers harmed by injections they received at clinics or med spas from attendants who might not have been properly licensed to give the shots. The agency also has heard from some consumers who bought the unapproved shots online and injected the drugs themselves. The FDA has approved only one injectable drug for dissolving fat, a prescription medication called Kybella, the agency said. The drug, which is deozycholic acid, is FDA-approved to treat double chins in adults. Deozycholic acid is a bile acid naturally produced by intestinal bacteria to help break down fats during digestion. The FDA warns that improper or unsafe injection practices can increase the risk of scarring, skin infections and serious complications. Safe and effective use of a fat-dissolving agent involves calculating the correct number and location of the injections, placing the needles properly, and administering the shots in a safe and sterile manner, the FDA said. Kybella's label notes that the shots should be administered only by a health care professional, the agency noted. People shouldn't buy fat-dissolving products from websites, much less attempt to inject them, the FDA added. Instead, they should consult their doctor about FDA-approved treatments like Kybella. Folks who have received these injections and are experiencing side effects should seek medical care. They also should report their case to the FDA's MedWatch program, which helps the agency track medication safety issues.
Pharmaceutical company Rusan Pharma has launched a new active pharmaceutical ingredients (API) manufacturing plant at Pithampur, Madhya Pradesh. At the opening, at the invitation of the company, the commercial director of Dori-Darmon JSC Nurali Khasanov and the head of Fargona Dori-Darmon JSC Muhammadamin Tursunov took part. The company is known for its innovative products in the treatment of drug addiction, Parkinson's disease, and products for the treatment of moderate to severe pain. They also produce nicotine transdermal patches for smoking cessation. The new plant will create 300 jobs and have a production capacity of 400 metric tons of API per year.The new facility will augment Rusan Pharma's existing API manufacturing capacity to supply critical APIs to meet the growing demand for its addiction treatment and pain management products in India and abroad. The joint stock company "Dori-Darmon" has been cooperating with Rusan Pharma for more than 20 years. Over many years of cooperation, the company has established itself as a reliable supplier of vital drugs. The team of AK "Dori-Darmon" congratulates Rusan Pharma on the opening of the new plant, wishes success and hopes that the cooperation of our companies will continue for many more decades!
A smartphone app using artificial intelligence technology to detect changes in the voice of a person with heart failure predicted more than 75% of hospitalizations about three weeks before they happened, according to late-breaking science presented Nov. 13 at the American Heart Association's Scientific Sessions 2023. The meeting, held Nov. 11–13, in Philadelphia, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. "Speech analysis is novel technology that may be a useful tool in remote monitoring of heart failure patients, providing early warning of worsening heart failure that frequently results in hospitalization," said lead study author William T. Abraham, M.D., FAHA, a professor of medicine, physiology and cell biology; and a College of Medicine Distinguished Professor in the division of cardiovascular medicine at The Ohio State University Wexner Medical Center in Columbus. "This technology has the potential to improve patient outcomes, keeping patients well and out of the hospital, through the implementation of proactive, outpatient care in response to voice changes." Heart failure occurs when the heart muscle can't pump enough blood to meet the body's needs for blood and oxygen. This can result in fatigue, fluid retention, shortness of breath and sometimes excessive coughing. This study evaluated the effectiveness of the artificial intelligence-driven mobile app to predict worsening heart failure in advance of any need for hospitalization and /or intravenous treatment among people diagnosed with heart failure. The mobile phone app was designed to detect changes in speech measures in patients over time. The voice changes could indicate early increases of lung fluid, which is a sign of progressing heart failure. The study was conducted from March 2018 through April 2023 and enrolled 416 adults living in Israel diagnosed with heart failure. Study participants recorded five sentences in their native language—Hebrew, Russian, Arabic or English—into the phone app daily. In a training phase of the study, distinct speech measures from 263 participants were used to develop the AI algorithm. Then, the algorithm was used in the remaining 153 participants to validate the tool's effectiveness. The analysis found: In the training phase of the study, the app accurately predicted 76% of worsening heart failure (44 of the 58 heart failure events) on average 24 days before hospitalization or the need for IV fluids occurred. The app generated an average of three unnecessary alerts per patient, per year. In the validation phase, the app was 71% accurate in detecting heart failure events about 3 weeks in advance (detecting 10 of 14 events). There were about three unexplained alerts per patient per year in this group as well. Researchers conclude that the technology detects future worsening heart failure episodes accurately, with a low unnecessary notification rate. This high rate of accuracy and early notification of worsening heart failure validate the AI tool as a potentially effective way to reduce hospitalization and improve patient outcomes. Study background: The technology used in this study was the Cordio HearO system, a remote monitoring system comprised of a smartphone-based mobile speech application. About 75% of the participants were men, and their average age was 68 years. The 263 patients in the training phase, made recordings on 83% of days between March 27, 2018—November 30, 2021 and were followed for up to 44 months. The test group of 153 patients made recordings on 81% of days between February 1,2020—April 30, 2023 and followed for up to 31 months. The distinct speech measures included pitch, volume, dynamics, and other characteristics. While statistically valid, the number of participants in the study was small, which is a limitation of the study. An ongoing U.S.-based study will add to the experience in further training and validating the technology, Abraham said.
The boss and three other officials of an Indonesian firm whose cough syrup was linked to the deaths of over 200 children have been sentenced to jail. They were handed two-year prison sentences and fined 1bn Indonesian rupiah ($63,056; £51,786). The firm, Afi Farma, was accused of producing cough syrups containing excess amounts of toxic substances. The company's lawyer said they denied negligence and the firm was considering whether to appeal. Prosecutors had been seeking a prison sentence of up to nine years for Afi Farma's chief executive, Arief Prasetya Harahap, and seven years each for the other defendants. The Public Prosecutor said that between October 2021 and February 2022 the company received two batches of propylene glycol, which is used for making cough syrup. These batches contained 96% to 99% ethylene glycol, the prosecutor said. Both substances can be used as additives to solvents. While, propylene glycol is non-toxic and widely used in medicines, cosmetics and food, ethylene glycol is toxic and used in paint, pens and brake fluid. The company did not test the ingredients used in the cough syrup and instead relied on quality and safety certificates from its supplier, prosecutors said. Afi Farma's lawyer, Samsul Hidayat, told the BBC that Indonesia's drug regulator did not require drug makers to carry out rigorous testing of ingredients. The judge in the Kediri District Court, East Java, found the four defendants guilty of intentionally producing pharmaceutical goods that did not meet safety standards. The case comes as efforts grow worldwide to tighten the oversight of drug supply chains after the poisonings. Since 2022, more than 200 Indonesian children, most of whom were under the age of five, have died of acute kidney injury linked to contaminated cough syrup. About 100 deaths have been reported in The Gambia and Uzbekistan. The World Health Organization (WHO) has issued warnings about six cough syrups made in India and Indonesia.
Inspira Technologies has developed a machine that can raise a patient's oxygen saturation to 95 percent or higher almost immediately (Courtesy) A new device developed by an Israeli startup that helps patients breathe when their lungs are unable to do so fully has just been patented in the US. The INSPIRA ART500, produced by Inspira Technologies, is a small box-shaped device that acts as an artificial lung. It draws small volumes of blood with low oxygen levels from patients and circulates it, enriches it with oxygen and removes carbon dioxide, and sends it back through a tube inserted into the neck. The startup has developed the device with the aim of reducing the need for mechanical ventilation systems. According to the company, these systems are associated with a 50 percent mortality rate, can heighten the risk of coma and even cause bacterial infections or other associated lung injuries related to mechanical ventilation. The newly granted patent relates to the module of the machine that prevents air bubbles within its pumps, thereby reducing the risk of the formation of clots which reduce blood flow. Inspira has also initiated patent applications in Europe and several countries in other regions. “We believe that this patent approval represents a further recognition of our unique solution alongside a major milestone towards the INSPIRA ART500 system and building a global medical solution,” said Dagi Ben-Noon, CEO of Inspira. “We are working diligently to convert our innovation into value for our shareholders.”
The delegation led by the Deputy Prime Minister of Uzbekistan Jamshid Khodjaev visited Kabul to further develop cooperation with the Islamic Emirate of Afghanistan.The "Made in Uzbekistan" exhibition organized at the International Business Center was attended by a group of industry officials under the leadership of Abdulla Azizov, director of the Pharmaceutical Industry Development Agency. More than 300 medical products were displayed. Also, meetings and negotiations were held in "B2B" format between representatives of the business circles of the two countries. About 4,000 medical products were presented at the exhibition.Director of the Pharmaceutical Service of the Ministry of Health of Afghanistan, Hamid Formuloy, made suggestions on simplifying the registration of the delivery of pharmaceuticals and products produced in Uzbekistan to Afghanistan.In this matter, practical assistance will be provided to establish cooperation with the National Association of Food and Medicines of Afghanistan, which has the authority to register medical products.Within the framework of the meetings, the issue of importing medicines, medical equipment and medical equipment from our country to private hospitals in this country and sending patients to Uzbekistan for treatment was discussed with the deputy of the Afghanistan Entrepreneurs' Advisory Council for health issues, Dr. Muhammad Hashim Wahaaj. Also, an agreement was reached on the visit of the Afghan delegation in order to get acquainted with medical products and treatment processes in Uzbekistan. Export-import issues were discussed with Zabihullah Momen Zada, a member of the Kabul Chamber of Commerce and Industry.
New medical research finds that artificial intelligence can detect type 2 diabetes merely by listening to a patient speak for six to ten seconds. The study by Klick Labs, published in “Mayo Clinic Proceedings: Digital Health,” showed an 89% accuracy rate for diagnoses in women and 86% for men, according to a release detailing the breakthrough. “Our research highlights significant vocal variations between individuals with and without Type 2 diabetes and could transform how the medical community screens for diabetes,” said first author Jaycee Kaufman. “Current methods of detection can require a lot of time, travel, and cost. Voice technology has the potential to remove these barriers entirely,” Kaufman continued. Researcher had 267 individuals — who did or did not have type 2 diabetes — record phrases on their smartphones six times a day for two weeks. More than 18,000 recordings were analyzed for over 14 different acoustic features, which were different among diabetics and non-diabetics. Participants also provided basic health data like age, height, and weight. Signal processing technologies were able to perceive certain notes of vocal pitch that do not register with the human ear. These hidden sounds provided the necessary clues, according to Kaufman. “Our research underscores the tremendous potential of voice technology in identifying Type 2 diabetes and other health conditions,” Klick VP and principal investigator Yan Fossat said. “Voice technology could revolutionize healthcare practices as an accessible and affordable digital screening tool.” The next step for Klick is replicating the study and expanding the vocal search to look for pre-diabetes, hypertension and more.
Drugmakers spent nearly $500 million on advertisements for obesity and diabetes treatments in the U.S. during the first seven months of this year, up 20% from the same period a year ago, according to new data released Friday. U.S. health-care providers wrote more than 9 million prescriptions for Ozempic, Wegovy, and other obesity and diabetes drugs during the last three months of 2022, up 300% from early 2020. The top four drugs advertised were Novo Nordisk’s Ozempic, Wegovy and diabetes pill Rybelsus and Boehringer Ingelheim’s own diabetes treatment Jardiance, which is set to face drug price negotiations with the federal Medicare program. Spending on Ozempic ads was $120 million during that time period, up 23% from the same period last year. MediaRadar said most of the spending on the drug was for digital advertising, such as online video.
In 2010 in Samarkand, in order to implement a project to organize the production of injectable drugs in accordance with international standards of GMP, the company “InegtraDD” LLC was established. The total area of the plant with developed infrastructure is 11,200.0 sq.m.
In 2007 “Dori Darmon HCP” LLC was established, represented in Uzbekistan under the brand name “Elysee Parfumerie”. The main activity is the retail sale of luxury cosmetics and perfumes.
In 2011, “DD General Insurance” JSC was founded, the main task of which is to provide reliable insurance protection of property interests of legal entities and individuals. Today the company has its own solid customer base of numerous types of voluntary insurance. At the end of 2021 rating agency “Standard and Sensitive Ratings” assigned to the company solvency and reliability rating according to the national scale “uzA++” (the highest) with the “Stable” outlook which means that the company has an outstanding ability to fulfill its obligations and claims of policy holders in time and in full. In the future it is planned to develop the direction of compulsory health insurance.
In 2005 an order was signed on the establishment of “Dori-Darmon Garant” LLC, with a customs warehouse with a total area of 2000 square meters, which provides modern storage service for imported medicines and medical devices. In 2012, for the first time in Uzbekistan was implemented a large-scale project of the concept “Smart warehouse”, which uses automated storage and logistics systems.
You can contact us with numbers +998 71 228-06-96 and 1002
344 raw materials and materials, medical products and packaging materials, imported for the purpose of drug preparation in the pharmacy, used for feeding laboratory animals, pre-clinical research and drug production (including drug preparation) that are not produced in the Republic of Uzbekistan, will be exempted from customs duties until January 1st 2025.
Вы можете связаться с нами по телефону +998 71 228-06-96 или же по короткому номеру 1002
First of all, it is recommended to use antiseptics to disinfect hands. Hydrogen peroxide and furacilin are mainly antibacterial agents. Since antiseptic agents contain 70 percent ethyl alcohol, they have the ability to destroy the shells of viruses.